SOST and bone metastasis: Consistently, anti-sclerostin antibody also reduces the volume of bone marrow adipose tissue [118,119], suggesting that the antitumor effect of sclerostin antibody in models of bone metastasis could also be mediated, at least in part, by the bone marrow adipocytes.